212,944 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Acquired by First Trust Advisors LP

First Trust Advisors LP bought a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 212,944 shares of the biopharmaceutical company's stock, valued at approximately $1,819,000. First Trust Advisors LP owned approximately 0.14% of Ocular Therapeutix as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in OCUL. Artisan Partners Limited Partnership raised its holdings in shares of Ocular Therapeutix by 26.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock valued at $11,398,000 after purchasing an additional 278,610 shares in the last quarter. Rosalind Advisors Inc. raised its stake in Ocular Therapeutix by 27.5% in the fourth quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock valued at $9,639,000 after buying an additional 243,700 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Ocular Therapeutix during the 4th quarter worth about $1,722,000. RoundAngle Advisors LLC purchased a new stake in Ocular Therapeutix during the 4th quarter worth about $1,695,000. Finally, Barclays PLC boosted its position in shares of Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock worth $4,451,000 after acquiring an additional 138,441 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company's stock.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on OCUL shares. JMP Securities set a $19.00 price target on Ocular Therapeutix in a report on Tuesday, March 4th. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. William Blair began coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating on the stock. Finally, Needham & Company LLC reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $16.38.

Ocular Therapeutix Price Performance

Shares of OCUL opened at $7.73 on Tuesday. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -5.86 and a beta of 1.51. Ocular Therapeutix, Inc. has a fifty-two week low of $4.79 and a fifty-two week high of $11.78. The firm has a 50-day simple moving average of $7.41 and a 200-day simple moving average of $8.36. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million during the quarter, compared to analysts' expectations of $16.89 million. On average, equities research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.